Effect of danicopan on complement biomarkers and GPI-deficient cell population. Serum, plasma, and whole blood samples were collected at day 1 prior to dosing danicopan (baseline [BL]) and at the indicated time points during the study and subjected to measurement of CP activity (A), AP activity with AP hemolysis assay (B), plasma Bb concentration (C), and the population size of GPI-deficient granulocytes, GPI-deficient erythrocytes, and C3d⁺ GPI-deficient erythrocytes (D), as described in Methods. Arithmetic mean and standard derivation (SD) are shown for all, with the range shown at each time point. LLN, lower limit of normal; NHS, normal human serum.